ENTITY

Newron Pharmaceuticals (NWRN SW)

32
Analysis
Health CareItaly
Newron Pharmaceuticals SpA is a research and development biopharmaceutical company. The Company focuses on and develops therapies for the Central Nervous System (CNS) in cases such as Parkinson's disease, neuropathic low back pain and other cognitive disorders.
more
26 Mar 2020 16:52Issuer-paid

Newron Pharmaceuticals - Seeing STARS

The statistical analysis plan for the pivotal STARS trial of sarizotan for symptomatic treatment of Rett syndrome should be FDA approved soon. This...

Share
11 Nov 2019 18:18Issuer-paid

Newron Pharmaceuticals - Xadago sales slow but STARS ahead

Newron Pharmaceuticals’ recently reported interim results highlight that despite additional worldwide launches of Xadago, sales growth in the US...

Share
04 Oct 2019 21:10Issuer-paid

Newron Pharmaceuticals - Xadago slows, Evenamide lags but STARS ahead

Newron Pharmaceuticals’ interim results highlight that despite additional worldwide launches of Xadago, sales growth in the US and Europe remain...

Share
04 Apr 2018 18:32Issuer-paid

Newron Pharmaceuticals - 2018 focus on the CNS pipeline

Xadago for Parkinson’s disease (PD) is now available in 14 European countries through partner, Zambon. Additionally, the drug is available in the...

Share
13 Oct 2017 15:18Issuer-paid

Xadago launched; eyes now on pipeline assets

Following an encouraging year to date we have upgraded our forecasts for Xadago (Parkinson’s disease [PD] therapy), and key CNS pipeline assets...

Share
x